EPB41L2: Potential Drug Targets and Biomarkers (G2037)

Target Name: EPB41L2

NCBI ID: G2037

EPB41L2

EPB41L2: Potential Drug Targets and Biomarkers

EPB41L2 (Epb41L2 variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, and skeletal muscles. It is a member of the E-cadherin gene family, which is known for its role in cell-cell adhesion and signaling. Despite its importance in these processes, little is known about EPB41L2 and its potential functions.

In recent years, researchers have been interested in exploring new drug targets and biomarkers that can be used to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. EPB41L2 is one of these proteins that has potential as a drug target or biomarker.

Disease-related functions of EPB41L2

EPB41L2 is involved in several physiological processes that are important for the health and function of various tissues. One of its key functions is cell-cell adhesion, which is the process by which cells stick together to form tissues and organs. In the brain,EPB41L2 plays a role in the formation and maintenance of neuronal cell types, and is also involved in the regulation of synaptic plasticity.

EPB41L2 is also involved in the regulation of cell proliferation and apoptosis, which are processes that are important for the growth and development of tissues. In addition, it is involved in the development and maintenance of tissues and organs, including blood vessels and bones.

Mutations in the EPB41L2 gene have been linked to a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that individuals with certain genetic mutations, such as those that result in the formation of cancerous tumors, have lower levels of EPB41L2 in their bodies.

Potential drug targets and biomarkers

The lack of information about EPB41L2's functions makes it an attractive target for researchers to explore new drug options. By targeting EPB41L2, researchers may be able to treat a variety of diseases that are caused by its absence or dysfunction.

One potential approach to targeting EPB41L2 is to use small molecules or antibodies that can modulate its activity. For example, researchers may try to identify molecules that can inhibit the formation of cancerous tumors that are caused by EPB41L2 mutations.

Another potential approach to targeting EPB41L2 is to use it as a biomarker for disease diagnosis or monitoring. For example, researchers may use EPB41L2 as a diagnostic marker to identify individuals who are at risk for developing certain diseases, such as cancer or neurodegenerative diseases.

Conclusion

EPB41L2 is a protein that is involved in several important physiological processes in the body. While more research is needed, its potential as a drug target or biomarker makes it an attractive target for researchers to explore. By targeting EPB41L2, researchers may be able to develop new treatments for a variety of diseases.

Protein Name: Erythrocyte Membrane Protein Band 4.1 Like 2

Functions: Required for dynein-dynactin complex and NUMA1 recruitment at the mitotic cell cortex during anaphase (PubMed:23870127)

The "EPB41L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPB41L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets